Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Nutrition and exercise for preventing and treating muscle loss

Updated

Abstract

A total of 37 randomized controlled trials (RCTs) were analyzed, indicating that 79% showed increased muscle mass from exercise in individuals aged 65 and older.

  • Physical exercise positively impacts muscle mass in 79% of studies involving older adults.
  • Muscle strength increased in 82.8% of studies following exercise interventions.
  • Only a small number of studies (23.5%) indicated additional benefits of dietary supplementation on muscle mass.
  • Increased physical performance was observed in 92.8% of studies after exercise intervention, with limited interaction from nutrition supplementation.
  • The variability in dietary supplementation protocols was significant across the included studies, suggesting no consistent effect on muscle function.

Simplified

Key numbers

27 of 34 RCTs
Increase in Muscle Mass
Percentage of studies showing muscle mass increase with exercise intervention.
29 of 35 RCTs
Increase in Muscle Strength
Percentage of studies showing muscle strength increase with exercise intervention.
26 of 28 RCTs
Improvement in Physical Performance
Percentage of studies reporting improved physical performance with exercise intervention.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

N Binkley received research support from Amgen, GE Healthcare, and Lilly, Merck and consultant/advisory board fees from Amgen, Astellas, Lilly, Merck, Nestle, and Radius. J-Y Reginster received consulting fees or paid advisory boards from Servier, Novartis, Negma, Lilly, Wyeth, Amgen, GlaxoSmithKline, Roche, Merckle, Nycomed-Takeda, NPS, IBSA-Genevrier, Theramex, UCB, Asahi Kasei, Endocyte, and Radius Health; lecture fees from Merck Sharp and Dohme, Lilly, Rottapharm, IBSA, Genevrier, Novartis, Servier, Roche, GlaxoSmithKline, Merckle, Teijin, Teva, Analis, Theramex, Nycomed, NovoNordisk, Ebewee Pharma, Zodiac, Danone, Will Pharma, Amgen, and PharmEvo; and grant support from Bristol Myers Squibb, Merck Sharp & Dohme, Rottapharm, Teva, Roche, Amgen, Lilly, Novartis, GlaxoSmithKline, Servier, Pfizer, Theramex, Danone, Organon, Therabel, Boehringer, Chiltern, and Galapagos. ML Brandi is a consultant and grant recipient from Alexion, Abiogen, Amgen, Bruno Farmaceutici, Eli Lilly, MSD, NPS, Shire, SPA, and Servier. C Beaudart, A Dawson, S Shaw, N Harvey, JA Kanis, R Chapurlat, D Chan, O Bruyère, R Rizzoli, C Cooper, EM Dennison, G Adib, T Chevalley, P Clark, B Dawson-Hughes, A El Maghraoui, K Engelke, R Fielding, J Foldes, G Guglielmi, JM Kaufman, B Larijani, W Lems, L van Loon, G Lyritis, S Maggi, L Masi, E McCloskey, OD Messina, A Papaioannou, P Szulc, and N Veronese have nothing to declare.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free